Eliglustat on Gaucher Disease Type IIIB

* This is a 3-year study and the enrollment time of this study is 24 months. * The participants have to receive the investigational agent:Cerdelga.(Cerdelga have 21 mg、42 mg and 84 mg capsule.) * The participants have to go back to the hospital and receive the investigational agent and take the Gaucher related biomarkers test before receiving Cerdelga, and 2 weeks, 1, 3, 6, 12, 18 and 24 months after receiving Cerdelga. * The participants have to inform if any adverse events happened. * The investigators will follow up by phone if adverse events happened in the participants after one months start the treatment.